Skip to Main Content

 

White Paper

Engineering Simulation: A Promising Tool for Securing Regulatory Approvals

Computational modeling and simulation (CM&S) is now widely used as a part of healthcare product and process development activities. By simulating the performance of healthcare devices and therapies in a low-risk, cost-effective virtual environment, the development process can be accomplished much faster and more cost-effectively. To date, CM&S technology has been largely ignored during the equally important and very costly regulatory approval process. Yet its acceptance for securing regulatory approvals is increasing, as more government agencies and other stakeholders are seeing its benefits. The United States Congress, the US Food & Drug Administration (FDA) and the European Parliament have all publicly recognized the value engineering simulation can add during the process of demonstrating product performance and gaining approvals. Today a number of healthcare companies and technology providers are joining forces within the Avicenna Alliance to accelerate the pace of adoption. With so many doors open, the failure to use engineering simulation as part of the regulatory approval process not only misses a major opportunity, but also wastes precious resources.

 

SHARE THIS WHITE PAPER

Ansys가 귀사를 위해 무엇을 할 수 있는지 알아보십시오.

문의하기

* = 필수 항목

문의해 주셔서 감사합니다!

We’re here to answer your questions and look forward to speaking with you. A member of our Ansys sales team will contact you shortly.

바닥글 이미지